Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rg-7603. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.78 |
| ▸ | RPTOR | Q8N122 | 5/20 | 0.75 |
| ▸ | MLST8 | Q9BVC4 | 5/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rg-7603 SCHEMBL25062086 | 1.00 | MTOR (1.00) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| Rg-7603 SCHEMBL1831520 | 1.00 | MTOR (1.00) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| Rg-7603 SCHEMBL29373340 | 1.00 | MTOR (1.00) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| SCHEMBL2098645 | 0.95 | MTOR (0.91) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| SCHEMBL1830460 | 0.95 | MTOR (0.91) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| SCHEMBL1830931 | 0.95 | MTOR (0.91) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| SCHEMBL2098648 | 0.95 | MTOR (0.91) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| SCHEMBL1832032 | 0.94 | MTOR (1.00) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| SCHEMBL1832036 | 0.94 | MTOR (1.00) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| SCHEMBL1832580 | 0.94 | MTOR (0.91) | MTORPIK3CACYP3A4KCNH2RPTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318377-B1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH INC (US) | 2013-08-21 | — | — | EP | claimed |
| US-8163763-B2 | Pyrimidine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | claimed |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-12527795-B2 | Compositions of adagrasib and mTOR inhibitors and methods of treatment therewith | Mirati Therapeutics, Inc. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250179077-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250163064-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-12291539-B2 | KRAS G12C inhibitors | FRONTIER MEDICINES CORPORATION (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250129103-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION | 2025-04-24 | — | — | US | disclosed |
| WO-2020055761-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-03-19 | — | — | WO | disclosed |
| US-20170348314-A1 | COMBINATION THERAPIES | HCR COLLATERAL MANAGEMENT, LLC | 2017-12-07 | — | — | US | disclosed |
| US-20150320754-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2015-11-12 | — | — | US | disclosed |
| EP-2318377-B1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8163763-B2 | Pyrimidine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2318377-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Genentech, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2010014939-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179077-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | KRAS, NRAS, HRAS | MTOR 764/4885PIK3CA 83/4885CYP3A4 2728/4885 |
| US-12527795-B2 | Compositions of adagrasib and mTOR inhibitors and methods of treatment therewith | KRAS, NRAS, HRAS | MTOR 19/4885PIK3CA 6/4885CYP3A4 4136/4885 |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | MTOR 1708/4885PIK3CA 179/4885CYP3A4 4013/4885 |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | MTOR 648/4885PIK3CA 81/4885CYP3A4 3307/4885 |
| US-20250163064-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | KRAS, NRAS, HRAS | MTOR 873/4885PIK3CA 86/4885CYP3A4 2895/4885 |
| US-20150320754-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | MTOR 24/4885PIK3CA 18/4885CYP3A4 2012/4885 |
| US-20170348314-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | MTOR 24/4885PIK3CA 18/4885CYP3A4 2012/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | MTOR 228/4885PIK3CA 338/4885CYP3A4 4258/4885 |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | MTOR 648/4885PIK3CA 81/4885CYP3A4 3307/4885 |
| US-12291539-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | MTOR 1519/4885PIK3CA 61/4885CYP3A4 4749/4885 |
| US-20250129103-A1 | METHODS FOR TREATMENT OF CANCER | KRAS, HRAS, TP53 | MTOR 2412/4885PIK3CA 107/4885CYP3A4 4571/4885 |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, TYMS, DTYMK | MTOR 1/4885PIK3CA 4/4885CYP3A4 1677/4885 |
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, TYMS, DTYMK | MTOR 1/4885PIK3CA 4/4885CYP3A4 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.